Endpoint
Body mass
CAT:outcome/body-massreported in kg36 findings from 22 compounds
What moved it
How to read these marks36 findings · 22 compounds · 10 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| berberine | down | 4 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| tirzepatide | down | 4 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| creatine | up | 2 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| L-arginine | no effect | 2 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| empagliflozin | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| Lactiplantibacillus plantarum | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| lipoic acid | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| Withania somnifera | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| Zn(2+) | up | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| curcumin | down 2 · no effect 2 | 4 | Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. |
| chromium(3+) | no effect | 1 | Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. |
| (-)-epigallocatechin 3-gallate | down | 4 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| 5-hydroxy-L-tryptophan | down | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| aripiprazole | up | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| aspartame | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| astaxanthin | up | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| caffeine | down | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| Collagen | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| L-cysteine | down | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| magnesium(2+) | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| resveratrol | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| sodium(1+) | down | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
Reported to move it
26 findings
berberine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“BBR exhibited greater decreases in body weight, BMI, waist, HFC, serum cholesterol and triglycerides compared with LSI alone (Additional file 1: Table S1), which demonstrates a clearly significant benefit of BBR on metabolism.”
Quoted verbatim from Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease.. - Study
- RCT
- Duration
- 4 months
- Dose
- berberine 0.5 g three times daily, 30 min before meals
- Population
- Adults with nonalcoholic fatty liver disease and impaired glucose regulation or type 2 diabetes; lifestyle intervention (diet and exercise) given to both arms, berberine added in one; 80-patient lipidomics subsample (41 berberine, 39 lifestyle alone)
Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease.2016PMID:27629750Permalink
tirzepatide — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“The pooled data analysis showed substantial weight reduction in all three tirzepatide doses compared to the placebo group.”
Quoted verbatim from Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.. - Study
- meta-analysis
- Dose
- 5, 10 and 15 mg once weekly
- Population
- Adults with or without type 2 diabetes in seven placebo-controlled trials, 12 to 72 weeks; all three doses
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.2024PMID:38850440Industry fundedPermalink
Zn(2+) — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Two studies showed significantly higher body weight with zinc supplementation (MD = 2.38; 95% CI 1.40 to 3.35; p < 0.00001; I 2 = 0%).”
Quoted verbatim from Effects of Zinc Supplementation on Glycemic Control, Insulin Resistance, Inflammation and Oxidative Stress in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- Adults and children with type 1 or type 2 diabetes, gestational diabetes or prediabetes in 18 pooled RCTs of zinc supplementation against placebo or standard care
Effect 2.38 mean difference, 95% CI 1.4 to 3.35
Effects of Zinc Supplementation on Glycemic Control, Insulin Resistance, Inflammation and Oxidative Stress in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42594341Permalink
berberine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“BBR supplementation significantly decreased weight compared to placebo (WMD = −0.84; 95%CI, −1.34 to −0.34; P < 0.001).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS and other populations)
Effect -0.84 mean difference, 95% CI -1.34 to -0.34
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
lipoic acid — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Overall weight loss was 1.27 kg (CI=-2.29 to -0.25) greater in ALA treatment compared to that in placebo group.”
Quoted verbatim from Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Adults in eight randomised, double-blind, placebo-controlled trials reporting weight, including patients with diabetes mellitus, metabolic syndrome, rheumatoid arthritis, non-alcoholic fatty liver disease and overweight or obesity; durations 8 to 52 weeks
Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials.2017PMID:28295905Permalink
tirzepatide — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“Compared with placebo, once‐weekly tirzepatide led to a substantial decrease in the percentage change in body weight, with an MD of −16.32% and a 95% CI of −18.35 to −14.29 (p < 0.0001).”
Quoted verbatim from Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Dose
- 5, 10 or 15 mg or maximum tolerated dose, once weekly
- Population
- Adults with overweight or obesity without diabetes, six placebo-controlled randomised trials of 18 to 88 weeks (five phase 3 SURMOUNT trials and one phase 1 trial)
Effect -16.32 mean difference, 95% CI -18.35 to -14.29
Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2025PMID:40510020Permalink
Show the remaining 20
creatine — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“The two-way ANOVA for body mass revealed a main effect of pre–post supplementation (p = 0.035, η2 = 0.28) and a pre–post x group interaction (p = 0.006, η2 = 0.42) with only the Cr group increasing body mass after supplementation by 0.99 ± 0.83 kg (+1.36%, p = 0.007).”
Quoted verbatim from Effects of Oral Creatine Supplementation on Power Output during Repeated Treadmill Sprinting.. - Study
- RCT
- Participants
- 8
- Duration
- 5 days
- Dose
- creatine monohydrate 75 mg/kg + 1 g glucose, 4 doses/day for 5 days (~22.3 ± 1.8 g Cr/day)
- Population
- recreationally active male university students, aged 19-30 years
Effects of Oral Creatine Supplementation on Power Output during Repeated Treadmill Sprinting.2022PMID:35334797Permalink
tirzepatide — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“Tirzepatide 15 mg/MTD produced an 18.04% greater reduction in body weight versus placebo (95% CI −19.86 to −16.22; p < 0.00001; I 2 = 77%).”
Quoted verbatim from Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 15 mg or maximum tolerated dose, once weekly
- Population
- Adults with obesity or overweight without diabetes, pooled across five phase 3 SURMOUNT placebo-controlled trials (six comparisons, N = 4022); percentage change in body weight
Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.2026PMID:42487213Permalink
tirzepatide — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“Pooled analysis demonstrated a reduction in body weight in patients receiving tirzepatide comparing with placebo (WMD=-10.80, 95%CI:-10.80 to -9.99, p < 0.00001), indicating a substantial effect of the treatment.”
Quoted verbatim from Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 5, 10 or 15 mg once weekly
- Population
- Adults with obesity or type 2 diabetes in placebo-controlled phase 1 to 3 trials, pooled across 5, 10 and 15 mg doses
Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.2025PMID:40747302Permalink
empagliflozin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Our study demonstrated that empagliflozin had significant effects on the following outcomes in AMI patients: weight reduction (SMD = −0.80, 95% CI = −1.15 to −0.45, p < 0.00001), LVGLS (SMD = −0.27, 95% CI = −0.48 to −0.06, p = 0.01), EF (SMD = 1.01, 95% CI = 0.63–1.38, p < 0.00001), and SBP (SMD = −0.54, 95% CI = −0.88 to −0.20, p = 0.002).”
Quoted verbatim from Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 10 mg daily in eight included trials, 25 mg daily in one
- Population
- Patients with acute myocardial infarction; pooled RCTs, empagliflozin versus placebo; secondary outcome
Effect -0.8 standardised mean difference, 95% CI -1.15 to -0.45
Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.2025PMID:40489293Permalink
Withania somnifera — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“However, significantly greater reductions in body weight and BMI were observed at weeks 4, 12, and 24 (P < 0.0001) with ARE compared to PL.”
Quoted verbatim from Efficacy and safety of Ashwagandha (Withania somnifera) root extract on stress and weight management in adults: a prospective, randomized, double-blind, placebo-controlled study.. - Study
- RCT
- Participants
- 91
- Duration
- 6 months
- Dose
- 300 mg twice daily for 24 weeks
- Population
- Adults aged 19-65 years with BMI 25.0-39.9 kg/m2 (overweight or obese)
Efficacy and safety of Ashwagandha (Withania somnifera) root extract on stress and weight management in adults: a prospective, randomized, double-blind, placebo-controlled study.2025PMID:41635453Permalink
curcumin — decreases
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Findingreplicated ×1“Curcumin resulted a significant reduction in BMI (SMD −0.37; 95% CI, −0.61, −0.13; P < 0.01), weight (SMD −0.23; 95% CI, −0.39, −0.06; P < 0.01), and WC levels (SMD −0.25; 95% CI, −0.44, −0.05; P = 0.01).”
Quoted verbatim from The Effects of Curcumin on Weight Loss Among Patients With Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- patients with metabolic syndrome and related disorders, compared to placebo (pooled random-effects meta-analysis)
Effect -0.23 standardised mean difference, 95% CI -0.39 to -0.06
The Effects of Curcumin on Weight Loss Among Patients With Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2019PMID:31249528Permalink
astaxanthin — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“However, the body weight of mice that received 25-100 mg/kg ATX was significantly increased compared to that of the TBI groups.”
Quoted verbatim from Astaxanthin attenuates total body irradiation-induced hematopoietic system injury in mice via inhibition of oxidative stress and apoptosis.. - Study
- animal · not in humans
- Duration
- 12 days
- Dose
- 25, 50 or 100 mg/kg by oral gavage from 3 days before to 7 days after irradiation
- Population
- Male C57BL/6 mice given 4 Gy total body irradiation; ATX 25, 50 or 100 mg/kg versus DMSO vehicle, weighed 12 days after irradiation (N = 5 per group)
Astaxanthin attenuates total body irradiation-induced hematopoietic system injury in mice via inhibition of oxidative stress and apoptosis.2017PMID:28115023Permalink
(-)-epigallocatechin 3-gallate — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“EGCG-treated (fed with a 60 kcal% high-fat diet supplemented with 1% EGCG) mice showed an obvious reduction in body weight, lipid deposition, and epididymal adipocytes size.”
Quoted verbatim from Green Tea Polyphenol (-)-Epigallocatechin Gallate (EGCG) Attenuates Neuroinflammation in Palmitic Acid-Stimulated BV-2 Microglia and High-Fat Diet-Induced Obese Mice.. - Study
- animal · not in humans
- Duration
- 8 weeks
- Dose
- 1% EGCG blended into the diet for 8 weeks
- Population
- Male C57BL/6J mice with high-fat-diet-induced obesity, EGCG-supplemented high-fat diet versus high-fat diet alone
Green Tea Polyphenol (-)-Epigallocatechin Gallate (EGCG) Attenuates Neuroinflammation in Palmitic Acid-Stimulated BV-2 Microglia and High-Fat Diet-Induced Obese Mice.2019PMID:31614951Permalink
curcumin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“Combined effect sizes suggested a significant effect of curcumin supplementation on reduced body weight (BW) (WMD: -0.94 kg, 95% CI: -1.40, -0.47) and body mass index (BMI) (WMD: -0.40 kg/m2, 95% CI: -0.60, -0.19), respectively.”
Quoted verbatim from The effects of curcumin on anthropometric and cardiometabolic parameters of patients with metabolic related diseases: a systematic review and dose-effect meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults with metabolism-related diseases, dose-effect meta-analysis of 31 RCTs
The effects of curcumin on anthropometric and cardiometabolic parameters of patients with metabolic related diseases: a systematic review and dose-effect meta-analysis of randomized controlled trials.2023PMID:35475714Permalink
creatine — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“Cr + RT increased total body mass (P = 0.004) and fat-free mass (P < 0.0001) with no effect on fat mass as compared with RT alone.”
Quoted verbatim from Creatine supplementation during resistance training in older adults-a meta-analysis.. - Study
- meta-analysis
- Population
- older adults (Cr 63.6±5.9y, placebo 64.2±5.4y), resistance training >=6wk, vs RT alone
Creatine supplementation during resistance training in older adults-a meta-analysis.2014PMID:24576864Permalink
aripiprazole — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“In terms of side effects, children/adolescents taking aripiprazole had a greater increase in weight, with a mean increase of 1.13 kg relative to placebo (95% CI 0.71 to 1.54, two studies, 308 children/adolescents, moderate-quality evidence), and had a higher risk ratio (RR) for sedation (RR 4.28, 95% CI 1.58 to 11.60, two studies, 313 children/adolescents, moderate-quality evidence) and tremor (RR 10.26, 95% CI 1.37 to 76.63, two studies, 313 children/adolescents, moderate-quality evidence).”
Quoted verbatim from Aripiprazole for autism spectrum disorders (ASD).. - Study
- meta-analysis
- Population
- Children and adolescents with autism spectrum disorder; two placebo-controlled RCTs of oral aripiprazole, eight weeks
Effect 1.13 mean difference, 95% CI 0.71 to 1.54
Aripiprazole for autism spectrum disorders (ASD).2016PMID:27344135Permalink
5-hydroxy-L-tryptophan — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Patients receiving 5-HTP significantly decreased their daily energy intake, by reducing carbohydrate and fat intake, and reduced their body weight.”
Quoted verbatim from Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients.. - Study
- RCT
- Duration
- 14 days
- Dose
- 750 mg/d
- Population
- overweight non-insulin dependent diabetic outpatients
Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients.1998PMID:9705024Permalink
(-)-epigallocatechin 3-gallate — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“Nevertheless, the body weight of mice belonging to the CE group was significantly lower than those belonging to the CW group, starting at the fourth week until the end of experimental treatment (p < 0.001).”
Quoted verbatim from Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet.. - Study
- animal · not in humans
- Duration
- 4 months
- Dose
- green tea extract 98% EGCG, 50 mg/kg/day by gavage
- Population
- Male Swiss mice on a control diet (AIN-93), CE group (green tea extract) versus CW group (water by gavage), 16 weeks; difference from week 4 onward
Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet.2015PMID:26536464Permalink
(-)-epigallocatechin 3-gallate — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“By contrast high fat-fed mice treated with EGCG showed a 21.7% reduction in the rate of body weight gain and a 9.4% decrease in final body weight (p < 0.05, Table 1).”
Quoted verbatim from (-)-Epigallocatechin-3-gallate increases the expression of genes related to fat oxidation in the skeletal muscle of high fat-fed mice.. - Study
- animal · not in humans
- Duration
- 4 months
- Dose
- 0.32% EGCG in the diet
- Population
- High-fat-fed C57bl/6J mice given 0.32% EGCG in the diet for 16 weeks versus high-fat-fed mice without EGCG; final body weight
(-)-Epigallocatechin-3-gallate increases the expression of genes related to fat oxidation in the skeletal muscle of high fat-fed mice.2011PMID:21779555Permalink
caffeine — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“For every doubling in caffeine intake, the mean reduction in weight, BMI, and fat mass increased 2 Beta-fold (20.29 = 1.22, 20.23 = 1.17, and 20.36 = 1.28), which corresponding to 22, 17, and 28 percent, respectively.”
Quoted verbatim from The effects of caffeine intake on weight loss: a systematic review and dos-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Adults in randomized controlled trials of caffeine intake; dose-response meta-analysis pooling 13 RCTs (606 participants total across the review).
The effects of caffeine intake on weight loss: a systematic review and dos-response meta-analysis of randomized controlled trials.2019PMID:30335479Permalink
berberine — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“After the 16-week BBR intervention, the NAFLD + BBR group (736 ± 20.80) exhibited a significant reduction in body weight compared with the NAFLD group (828.67 ± 86.78) (P < 0.05, Fig. 3a).”
Quoted verbatim from Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.. - Study
- animal · not in humans
- Dose
- 150 mg/kg body weight per day by gavage for 16 weeks
- Population
- Male Sprague-Dawley rats with high-fat-diet-induced non-alcoholic fatty liver disease; berberine versus normal-saline gavage, body weight at end of 16-week intervention
Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.2017PMID:28241817Permalink
berberine — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“These results showed at 20 weeks the body weight significantly increased in HF group compared with NCD group (P<0.01), whereas BBR significantly suppressed body weight of mice with a high-fat diet in a dose-dependent manner (P<0.01).”
Quoted verbatim from Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway.. - Study
- animal · not in humans
- Dose
- 25 or 100 mg/kg daily by gavage, from 14 to 20 weeks of age
- Population
- Male C57BL/6J mice fed a high-fat diet; berberine 25 and 100 mg/kg versus saline gavage, body weight at 20 weeks of age
Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway.2021PMID:34421358Permalink
L-cysteine — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“To test this hypothesis, we gavaged mice with cysteine and observed a decrease in body weight and fat storage.”
Quoted verbatim from Dietary cysteine drives body fat loss via FMRFamide signaling in Drosophila and mouse.. - Study
- animal · not in humans
- Participants
- 10
- Duration
- 2 months
- Dose
- cysteine 4 mmol/kg per day, oral gavage, 60 days
- Population
- C57BL/6J male mice, orally gavaged with cysteine vs water
Dietary cysteine drives body fat loss via FMRFamide signaling in Drosophila and mouse.2023PMID:37055592Permalink
sodium(1+) — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Supplemental sodium with furosemide significantly decreased serum creatinine (pooled net mean difference [NMD]: -0.33 mg/dL, 95% confidence interval [CI]: [-0.50 to -0.17]), brain natriuretic peptide (pooled NMD: -62.84 pg/mL, 95% CI: [-103.61 to -22.08]), and weight (pooled NMD: -2.48 kg, 95% CI: [-4.31 to -0.66]).”
Quoted verbatim from Prescribed in-hospital sodium intake for decompensated heart failure: A systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- Patients hospitalized for acute decompensated heart failure; supplemental sodium plus furosemide versus furosemide alone (furosemide in both arms); oral and intravenous sodium trials pooled
Effect -2.48 mean difference, 95% CI -4.31 to -0.66
Prescribed in-hospital sodium intake for decompensated heart failure: A systematic review and meta-analysis.2025PMID:40450575Permalink
(-)-epigallocatechin 3-gallate — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“As indicated in Figure 1, EGCG treatment reduced body weight by 10% and gonadal WAT (gWAT) mass by 20%.”
Quoted verbatim from Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues.. - Study
- animal · not in humans
- Duration
- 14 days
- Dose
- 20 mg/kg/day by oral gavage for 2 weeks
- Population
- Male C57BL/6 mice fed a high-fat diet for 8 weeks, then treated with EGCG or vehicle for 2 weeks under continued high-fat diet
Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues.2020PMID:33050029Permalink
Measured, no effect detected
10 findings
Lactiplantibacillus plantarum — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“After 6 weeks of administration, no significant differences in BW, BMI, and body fat mass were observed between the Control and TWK10‐HK groups.”
Quoted verbatim from Effects of heat-killed Lactiplantibacillus plantarum TWK10 on exercise performance, fatigue, and muscle growth in healthy male adults.. - Study
- RCT
- Duration
- 6 weeks
- Dose
- 3 × 10^10 heat-killed cells/day (two 1.5 × 10^10 capsules) after meals
- Population
- Healthy untrained males aged 20-40 years; body weight measured before and after 6 weeks
Effects of heat-killed Lactiplantibacillus plantarum TWK10 on exercise performance, fatigue, and muscle growth in healthy male adults.2023PMID:37816697Industry fundedPermalink
L-arginine — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“Six weeks of l-arginine supplementation did not influence body weight, BMI, fat mass or lean mass in either of the ethnic groups (Table 2).”
Quoted verbatim from Effect of L-arginine on energy metabolism, skeletal muscle and brown adipose tissue in South Asian and Europid prediabetic men: a randomised double-blinded crossover study.. - Study
- crossover
- Duration
- 6 weeks
- Dose
- 9 g/day L-arginine, divided over three servings
- Population
- Prediabetic overweight South Asian and Europid men
Effect of L-arginine on energy metabolism, skeletal muscle and brown adipose tissue in South Asian and Europid prediabetic men: a randomised double-blinded crossover study.2019PMID:30377712Permalink
chromium(3+) — no detected effect on
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull result“Six months of chromium supplementation (500 mcg or 1000 mcg) was not associated with any significant changes in glycohemoglobin, weight, waist circumference, BMI, blood pressure, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, or urine microalbumin compared with placebo.”
Quoted verbatim from Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.. - Study
- crossover
- Duration
- 6 months
- Dose
- chromium picolinate 500 mcg or 1000 mcg daily
- Population
- Adults with impaired glucose tolerance, impaired fasting glucose or metabolic syndrome, without diabetes; modified cross-over, 6 months of chromium picolinate versus placebo
Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.2011PMID:20634174Industry fundedPermalink
Collagen — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Treatment with ACP (200, 400 and 800 mg/kg body weight), CCP and proline (400 mg/kg body weight) for 8 weeks caused no statistically significant differences in the body weight compared with the untreated model group.”
Quoted verbatim from Effect of Orally Administered Collagen Peptides from Bovine Bone on Skin Aging in Chronologically Aged Mice.. - Study
- animal · not in humans
- Duration
- 8 weeks
- Dose
- ACP 200, 400 or 800 mg/kg body weight and CCP 400 mg/kg body weight once daily by gavage
- Population
- 13-month-old female Kunming mice given bovine bone collagen peptides by gavage for 8 weeks against an untreated aged model group given saline; body weight
Effect of Orally Administered Collagen Peptides from Bovine Bone on Skin Aging in Chronologically Aged Mice.2017PMID:29099747Permalink
magnesium(2+) — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Serum potassium (4.1±0.1 vs 4.0±0.1 mmol/l, p=0.642) and calcium concentrations (corrected for serum albumin 2.4±0.0 vs 2.4±0.0 mmol/l, p=0.960) were similar after magnesium compared with placebo, as was body weight (92.5±3.9 vs 93.2±4.1 kg, p=0.142) (Table 2).”
Quoted verbatim from Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial.. - Study
- crossover
- Participants
- 14
- Duration
- 6 weeks
- Dose
- 15 mmol magnesium per day (360 mg) as magnesium gluconate liquid, 50 ml three times daily, for 6 weeks
- Population
- Adults with insulin-treated type 2 diabetes and serum magnesium at or below 0.79 mmol/l, 14 participants
Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial.2024PMID:37922013Permalink
curcumin — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1“Anthropometric parameters including weight, BMI, waist circumference, hip circumference, arm circumference, and body fat remained statistically unchanged by the end of trial (p > 0.05).”
Quoted verbatim from Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.. - Study
- crossover
- Duration
- 4 weeks
- Dose
- 1 g/day for 30 days
- Population
- obese individuals
Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.2013PMID:22610853Permalink
Show the remaining 4
curcumin — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1“However, no significant effects of curcumin supplementation on body weight were found.”
Quoted verbatim from The effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults with nonalcoholic fatty liver disease (NAFLD), pooled across 8 RCTs (520 participants)
The effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose-response meta-analysis of randomized controlled trials.2020PMID:31799714Permalink
L-arginine — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1“However, L-arginine intervention had not elicited a significant effect on BMI (WMD: -0.51 kg/m2; 95% CI: -1.11 to .08, P = 0.09) and body weight (WMD: -0.57 kg; 95% CI: -1.77 to 0.61, P = 0.34).”
Quoted verbatim from The effect of L-arginine supplementation on obesity-related indices: A systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Population
- humans
Effect -0.57 mean difference, 95% CI -1.77 to 0.61
The effect of L-arginine supplementation on obesity-related indices: A systematic review and meta-analysis of randomized clinical trials.2021PMID:30982445Permalink
aspartame — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Body weight did not change after aspartame consumption compared to control (5.00 kg; 95% CI, -1.56 to 11.56) or to sucrose (3.78 kg; 95% CI, -2.18 to 9.74).”
Quoted verbatim from Metabolic effects of aspartame in adulthood: A systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Population
- adults, pooled randomized clinical trials
Metabolic effects of aspartame in adulthood: A systematic review and meta-analysis of randomized clinical trials.2018PMID:28394643Permalink
resveratrol — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“The effects of resveratrol on body weight and Interleukin-6 levels of participants were not significant.”
Quoted verbatim from Effects of resveratrol on the anthropometric indices and inflammatory markers: an umbrella meta-analysis.. - Study
- meta-analysis
- Population
- Adults; umbrella meta-analysis pooling 19 meta-analyses of 81 RCTs of resveratrol supplementation (anthropometric and inflammatory outcomes).
Effects of resveratrol on the anthropometric indices and inflammatory markers: an umbrella meta-analysis.2024PMID:38374352Permalink
How it is measured
Total body mass on a calibrated scale under stated conditions — time of day, fasted or fed, recorded with each finding.
Measured, not recorded
- Subject
- body mass
- Measurements
- 35 measurements
- Recorded as a finding
- No
Show what was measured
body mass
increases
Creatine supplementation increased body mass, especially during longer-term interventions (≥6 wk) or when combined with structured resistance training.
PMID:40755023 · both readings recorded this
Body mass
no effect, p = 0.64, n = 19
Body mass was not different between trials (71.3 ± 2.6 vs. 71.6 ± 2.6 kg; P = 0.64)
PMID:19952844 · one of two readings recorded this
body mass
decreases
Among these, six showed a decrease in body mass of individuals, with consequent loss of weight
PMID:22566308 · one of two readings recorded this
body mass
decreases, p = 0.001
Following altitude exposure, body mass fell by 3 kg in all subjects (p<0.001)
PMID:24661196 · one of two readings recorded this
body mass
no effect
Not recorded as a finding: Stated as unchanged within the same baseline-referenced (within-arm) sentence as the FMD finding; no between-arm contrast given.
Endothelial function, measured by brachial artery flow-mediated dilation, increased 45-60% vs. baseline (P < 0.10) without changes in body mass or blood lipids.
PMID:26607249 · one of two readings recorded this
body mass
no effect, p = 0.05
at 16 weeks (i.e., after four weeks of supplementation (Q = 51.1 ± 0.6 g, E = 50.6 ± 0.8 g, EQ = 50.5 ± 0.5 g, and control = 50.2 ± 0.7 g; p > 0.05)
PMID:28753942 · one of two readings recorded this
body mass
no effect, p = 0.05
Body mass was also similar among groups at 12 weeks (Q = 47.3 ± 0.7 g, E = 47.1 ± 0.8 g, EQ = 47.1 ± 0.8 g, and control = 47.1 ± 1.0 g; p > 0.05)
PMID:28753942 · one of two readings recorded this
body mass
increases
PL | 67.1 ± 10.1 | 68.3 ± 10.6 a | 0.10 | 0.18, 2.13
PMID:30064450 · one of two readings recorded this
body mass
increases
Body Mass (kg) | B | 70.2 ± 13.8 | 70.9 ± 13.8 a | 0.06 | −0.55, 1.93
PMID:30064450 · one of two readings recorded this
Body mass
increases, p = 0.05
Both groups experienced similar increases in body mass over time (CR: pre 80.55 ± 18.07 kg, post 81.72 ± 17.44 kg; PLA: pre 79.88 ± 19.97 kg, post 80.14 ± 18.95 kg; p = 0.05; observed power = 0.51)
PMID:32599716 · one of two readings recorded this
Body mass
increases, p = 0.05
Both groups experienced similar increases in body mass over time (CR: pre 80.55 ± 18.07 kg, post 81.72 ± 17.44 kg; PLA: pre 79.88 ± 19.97 kg, post 80.14 ± 18.95 kg; p = 0.05; observed power = 0.51)
PMID:32599716 · one of two readings recorded this
body mass
decreases, p = 0.01
we detected reduced body mass in all experimental groups compared to IR group (p = 0.01)
PMID:32964031 · one of two readings recorded this
Body mass
no effect, p = 0.058
but the effect size indicated a moderate effect (p = 0.058, g = 0.57)
PMID:33802283 · one of two readings recorded this
Body mass
increases, p = 0.016
The body mass increase was statistically significant in the creatine condition by +1.2 ± 1.4% (+1.0 ± 1.2 kg, p = 0.016, g = 0.83)
PMID:33802283 · one of two readings recorded this
Body mass
decreases, p = 0.006
and decreased statistically in the placebo condition (−0.5 ± 0.8%, −0.4 ± 0.7 kg, p = 0.006, g = 1.0)
PMID:33802283 · one of two readings recorded this
Body mass
no effect
After | 69.1 | ± | 9.3 | 62.0 | - | 76.3 | 69.0 | ± | 8.7 | 62.3 | - | 75.6
PMID:34127014 · one of two readings recorded this
Body mass
Body mass | (kg) | Before | 68.0 | ± | 9.9 | 60.4 | - | 75.6 | 67.0 | ± | 9.0 | 60.1 | - | 73.9
PMID:34127014 · one of two readings recorded this
Body mass
no effect
After | 69.1 | ± | 9.3 | 62.0 | - | 76.3 | 69.0 | ± | 8.7 | 62.3 | - | 75.6
PMID:34127014 · one of two readings recorded this
Body mass
Body mass | (kg) | Before | 68.0 | ± | 9.9 | 60.4 | - | 75.6 | 67.0 | ± | 9.0 | 60.1 | - | 73.9
PMID:34127014 · one of two readings recorded this
body mass
no effect, p = 0.631
body mass (WMD: -0.15 kg; 95% CI: -0.78 to 0.47; p = 0.631, I2 = 0.0%, p = 0.998)
PMID:35813845 · one of two readings recorded this
Body mass
no effect
Body Mass (kg) | 72.10 ± 12.50 | 72.17 ± 11.69 | 72.44 ± 12.34 | 73.47 ± 12.34 | 73.85 ± 12.47 | 74.03 ± 12.64 | –
PMID:36778595 · one of two readings recorded this
Body mass
no effect
Body Mass (kg) | 72.10 ± 12.50 | 72.17 ± 11.69 | 72.44 ± 12.34 | 73.47 ± 12.34 | 73.85 ± 12.47 | 74.03 ± 12.64 | –
PMID:36778595 · one of two readings recorded this
body mass
no effect, p = 0.38
Body Mass, kg | 70 ± 11 | 69 ± 11 | 0.38
PMID:38110301 · one of two readings recorded this
body mass
increases
led to increased body mass (6.3%) and fat-free mass (6.3%) compared to placebo
PMID:39408252 · one of two readings recorded this
body mass
n = 244
Body mass was examined in 12 studies involving 244 participants.
PMID:39796467 · one of two readings recorded this
body mass
no effect, Welch's ANOVA p = 0.111, p = 0.111, n = 33
However, there was no significant difference between groups regarding mean ∆ in body mass (Welch's ANOVA: p = 0.111, η2 xp = 0.188).
PMID:40470618 · one of two readings recorded this
body mass
increases, +1.56 ± 0.57 kg in CM group (p<0.01); no change in PLA; between-group difference not detectable, n = 15
A time × treatment effect (p < 0.05) for body mass and fat‐free mass was seen, but differences between groups were not detectable.
PMID:40939139 · one of two readings recorded this
body mass
increases, WMD: 0.89 kg; 95% CI: 0.76, 1.01, p = 0.001
The meta-analysis of 60 effect sizes from 52 studies revealed a significant increase in body mass following Cr supplementation (WMD: 0.89 kg; 95% CI: 0.76,1.01; p < 0.001).
PMID:41433021 · one of two readings recorded this
body mass
increases, p = 0.01, n = 60
Post-hoc comparisons (Fig. indicated that body mass in the CR, CRCHO, and CRCPS was higher at post-supplementation compared to baseline (p = 0.026 for CR; p < 0.01 for CRCHO and CRCPS).
PMID:41888192 · one of two readings recorded this
body mass
unclear, p = 0.001
Post hoc Bonferroni comparisons confirmed that both EX and EX + SUP differed significantly from both CON and SUP at post-test (all four comparisons: p < 0.001)
PMID:42514394 · one of two readings recorded this
body mass
modulates, p = 0.013
a significant Group × Time interaction (F(3,40) = 4.040, p = 0.013, ηp2 = 0.233)
PMID:42514394 · one of two readings recorded this
body mass
no effect, p = 0.562
Paired analyses revealed no significant change in CON (p = 0.562, d = 0.18) or SUP (p = 0.351, d = 0.29)
PMID:42514394 · one of two readings recorded this
body mass
decreases, p = 0.003
EX + SUP generated the greatest absolute reduction (Δ = −5.50 kg, t(10) = −3.89, p = 0.003, d = 1.17; 95% CI [−8.65, −2.35] kg)
PMID:42514394 · one of two readings recorded this
body mass
decreases, p = 0.047
EX produced a moderate, statistically significant reduction (Δ = −2.70 kg, t(10) = −2.26, p = 0.047, d = 0.68; 95% CI [−5.36, −0.04] kg)
PMID:42514394 · one of two readings recorded this
body mass
no effect, p = 0.351
Paired analyses revealed no significant change in CON (p = 0.562, d = 0.18) or SUP (p = 0.351, d = 0.29)
PMID:42514394 · one of two readings recorded this
Sources cited
36 papers
- Subject
- body mass
- Findings
- 36
- Papers
- 36
Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.record2026PMID:424872131 finding
Effects of Zinc Supplementation on Glycemic Control, Insulin Resistance, Inflammation and Oxidative Stress in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2026PMID:425943411 finding
Efficacy and safety of Ashwagandha (Withania somnifera) root extract on stress and weight management in adults: a prospective, randomized, double-blind, placebo-controlled study.record2025PMID:416354531 finding
Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.record2025PMID:404892931 finding
Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.record2025PMID:407473021 finding
Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2025PMID:405100201 finding
Prescribed in-hospital sodium intake for decompensated heart failure: A systematic review and meta-analysis.record2025PMID:404505751 finding
Effects of resveratrol on the anthropometric indices and inflammatory markers: an umbrella meta-analysis.record2024PMID:383743521 finding
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.record2024PMID:388504401 finding
Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial.record2024PMID:379220131 finding
Dietary cysteine drives body fat loss via FMRFamide signaling in Drosophila and mouse.record2023PMID:370555921 finding
Effects of heat-killed Lactiplantibacillus plantarum TWK10 on exercise performance, fatigue, and muscle growth in healthy male adults.record2023PMID:378166971 finding
The effects of curcumin on anthropometric and cardiometabolic parameters of patients with metabolic related diseases: a systematic review and dose-effect meta-analysis of randomized controlled trials.record2023PMID:354757141 finding
Effects of Oral Creatine Supplementation on Power Output during Repeated Treadmill Sprinting.record2022PMID:353347971 finding
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.record2022PMID:363130961 finding
Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway.record2021PMID:344213581 finding
The effect of L-arginine supplementation on obesity-related indices: A systematic review and meta-analysis of randomized clinical trials.record2021PMID:309824451 finding
Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues.record2020PMID:330500291 finding
The effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose-response meta-analysis of randomized controlled trials.record2020PMID:317997141 finding
Effect of L-arginine on energy metabolism, skeletal muscle and brown adipose tissue in South Asian and Europid prediabetic men: a randomised double-blinded crossover study.record2019PMID:303777121 finding
Green Tea Polyphenol (-)-Epigallocatechin Gallate (EGCG) Attenuates Neuroinflammation in Palmitic Acid-Stimulated BV-2 Microglia and High-Fat Diet-Induced Obese Mice.record2019PMID:316149511 finding
The effects of caffeine intake on weight loss: a systematic review and dos-response meta-analysis of randomized controlled trials.record2019PMID:303354791 finding
The Effects of Curcumin on Weight Loss Among Patients With Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2019PMID:312495281 finding
Metabolic effects of aspartame in adulthood: A systematic review and meta-analysis of randomized clinical trials.record2018PMID:283946431 finding
Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials.record2017PMID:282959051 finding
Astaxanthin attenuates total body irradiation-induced hematopoietic system injury in mice via inhibition of oxidative stress and apoptosis.record2017PMID:281150231 finding
Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.record2017PMID:282418171 finding
Effect of Orally Administered Collagen Peptides from Bovine Bone on Skin Aging in Chronologically Aged Mice.record2017PMID:290997471 finding
Aripiprazole for autism spectrum disorders (ASD).record2016PMID:273441351 finding
Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease.record2016PMID:276297501 finding
Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet.record2015PMID:265364641 finding
Creatine supplementation during resistance training in older adults-a meta-analysis.record2014PMID:245768641 finding
Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.record2013PMID:226108531 finding
(-)-Epigallocatechin-3-gallate increases the expression of genes related to fat oxidation in the skeletal muscle of high fat-fed mice.record2011PMID:217795551 finding
Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.record2011PMID:206341741 finding
Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients.record1998PMID:97050241 finding